New-onset refractory status epilepticus (NORSE) is characterized by new, treatment-resistant status epilepticus in patients without prior epilepsy or clear acute structural, toxic, or metabolic causes, often requiring early use of continuous anesthetic infusions and immunotherapy to reduce morbidity and mortality.